
<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<title>AGA Clinical Practice Update on the Management of Ascites, Volume Overload, and Hyponatremia in Cirrhosis: Expert Review</title>
<style>

<style>
/* ===== GENERAL LAYOUT ===== */
body {
    font-family: 'Segoe UI', Tahoma, Geneva, Verdana, sans-serif;
    background: linear-gradient(135deg, #eef2ff, #fafafa);
    color: #2c2c2c;
    padding: 30px;
    margin: 0;
}

/* Centered mindmap container */
.mindmap {
    max-width: 800px;
    margin: auto;
    font-size: 20px;
    line-height: 1.7;
}

/* ===== LISTS ===== */
.mindmap ul {
    margin: 0.6em 0 1em 1.5em;
    padding-left: 1.4em;
    list-style: disc;
    color: #555;
    font-size: 0.95em;
    font-weight: 400;
    line-height: 1.6;
}

.mindmap li::marker {
    color: #8b5cf6; /* accent bullet color */
}

.mindmap li {
    margin-bottom: 6px;
    padding-left: 4px;
}

/* ===== COLLAPSIBLE SECTIONS ===== */
.mindmap details {
    /* FIX: Increased border width and used a darker color */
    border-left: 5px solid #7c3aed; 
    background: #ffffff;
    margin: 8px 0;
    /* FIX: Corrected typo "20x" to "20px" */
    padding: 9px 25px; 
    border-radius: 20px;
    box-shadow: 0 4px 12px rgba(139, 92, 246, 0.1);
    transition: all 0.3s ease;
    position: relative;
}

/* Subsection (nested details) */
.mindmap details > div > details {
    margin-left: -8px;
    /* FIX: Used a darker, more saturated color for the nested border */
    border-color: #9333ea; 
    background: #faf7ff;
}

/* Subtle hover feedback */
.mindmap details:hover {
    box-shadow: 0 6px 18px rgba(139, 92, 246, 0.18);
    background: linear-gradient(135deg, #ffffff, #f5f0ff);
}

/* ===== SUMMARY HEADERS ===== */
.mindmap summary {
    cursor: pointer;
    font-size: 1.1em;
    font-weight: 600;
    list-style: none;
    position: relative;
    /* FIX: Increased padding slightly to prevent text from touching the arrow icon */
    padding-left: 24px; 
    color: #4c1d95;
    outline: none;
}

/* Custom arrow icon */
.mindmap summary::before {
    content: "▶";
    position: absolute;
    left: 0;
    top: 2px;
    transition: transform 0.3s ease;
    font-size: 1em;
    color: #7c3aed;
}

/* Rotated arrow when open */
.mindmap details[open] > summary::before {
    transform: rotate(90deg);
}

/* Section title emphasis */
.mindmap summary strong {
    display: block;
    font-size: 1.25em;
    color: #4c1d95;
}

.mindmap summary em {
    font-style: normal;
    color: #6b21a8;
    font-size: 0.95em;
}

/* Open section highlighting */
.mindmap details[open] > summary {
    background: #f3e8ff;
    border-radius: 8px;
    padding: 6px 10px;
}

/* Smooth fade for expanded content */
.mindmap details[open] > div {
    animation: fadeIn 0.3s ease-in;
}

/* ===== DESCRIPTION BOXES ===== */
.mindmap .desc-box {
    background: #fdfcff;
    border: 2px solid #e5d9fb;
    border-left: 4px solid #c084fc;
    padding: 6px 10px;
    margin: 12px 0 18px 0;
    border-radius: 12px;
    box-shadow: 0 1px 3px rgba(160, 104, 255, 0.05);
    transition: background 0.3s ease;
}
.mindmap .desc-box:hover {
    background: #f8f4ff;
}

/* ===== ANIMATIONS ===== */
@keyframes fadeIn {
    from { opacity: 0; transform: translateY(-3px); }
    to { opacity: 1; transform: translateY(0); }
}

/* ===== BUTTONS ===== */
button {
    background-color: #7c3aed;
    color: white;
    border: none;
    padding: 10px 16px;
    margin: 0 6px;
    font-size: 2em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease, transform 0.2s ease;
}
button:hover {
    background-color: #6b21a8;
    transform: scale(1.05);
}

/* ===== FLOATING CONTROL PANEL ===== */
#level-controls {
    position: fixed;
    bottom: 30px;
    left: 85%;
    transform: translateX(-50%);
    background: rgba(255, 255, 255, 0.05);
    padding: 10px 16px;
    border-radius: 12px;
    box-shadow: 0 4px 12px rgba(0, 0, 0, 0.15);
    z-index: 9999;
    backdrop-filter: blur(6px);
    cursor: move;
    display: flex;
    align-items: center;
    gap: 6px;
}

/* Buttons inside the panel */
#level-controls button {
    background-color: rgba(124, 58, 237, 0.85);
    color: white;
    border: none;
    padding: 8px 14px;
    font-size: 2em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease, transform 0.2s ease;
}
#level-controls button:hover {
    background-color: rgba(107, 33, 168, 0.95);
    transform: scale(1.05);
}

/* Search input inside panel */
#level-controls input {
    border: 1px solid #d5c4ff;
    border-radius: 8px;
    padding: 7px 10px;
    font-size: 0.95em;
    outline: none;
    width: 150px;
    transition: border-color 0.2s ease;
}
#level-controls input:focus {
    border-color: #8b5cf6;
}

/* Search count text */
#searchCount {
    margin-left: 8px;
    font-style: italic;
    color: #4c1d95;
    font-size: 0.9em;
}

/* ===== SEARCH HIGHLIGHT ===== */
mark.search-highlight {
    background-color: #fff59d;
    color: #000;
    border-radius: 3px;
    padding: 1px 3px;
}



/* ===== CLICK-TO-REVEAL: Spoiler Blur Style ===== */
.mindmap q {
    cursor: pointer;
    color: transparent;
    /* Apply a text-shadow with the same color as the text to create the blur effect */
    text-shadow: 0 0 8px #2c2c2c; 
    user-select: none;
    transition: text-shadow 0.3s ease;
}

.mindmap q:hover {
    text-shadow: 0 0 4px #2c2c2c; /* Reduce blur on hover */
}

/* Style for the revealed text */
.mindmap q.is-revealed {
    color: inherit;
    text-shadow: none;
    cursor: default;
    user-select: text;
}




/*for full control button*/
/* ===== CLICK-TO-REVEAL: Spoiler Blur Style (with Read Mode) ===== */

/* This rule applies the blur ONLY when the mindmap is NOT in read-mode. */
.mindmap:not(.read-mode) q {
    cursor: pointer;
    color: transparent;
    text-shadow: 0 0 8px #2c2c2c; 
    user-select: none;
    transition: text-shadow 0.3s ease, color 0.3s ease;
}

.mindmap:not(.read-mode) q:hover {
    text-shadow: 0 0 4px #2c2c2c; /* Reduce blur on hover */
}

/* This combined rule handles BOTH cases for revealing text:
   1. The entire mindmap is in read-mode.
   2. An individual <q> has been clicked (in quiz mode).
*/
.mindmap.read-mode q,
.mindmap q.is-revealed {
    color: inherit;
    text-shadow: none;
    cursor: default;
    user-select: text;
}


</style>

</style>
</head>
<body>

<!-- Updated Controls -->
<div id="level-controls" onmousedown="dragElement(this)">
    <button onclick="zoomIn()">+</button>
    <button onclick="zoomOut()">-</button>
    <button onclick="resetView()">=</button>
    <!-- NEW: READ MODE TOGGLE BUTTON -->
    <button onclick="toggleReadMode()">Q/R</button>
</div>

<div class="mindmap">

    <div class="mindmap">
        
        <details>
            <summary><strong>AGA Clinical Practice Update on the Management of Ascites, Volume Overload, and Hyponatremia in Cirrhosis: Expert Review</strong></summary>
            <div>
                <ul><li>Journal: Gastroenterology | Publication Date: 2025 | DOI: https://doi.org/10.1053/j.gastro.2025.08.029</li></ul>
                
        <details>
            <summary><strong>Knowledge Test</strong></summary>
            <div>
                <ul><li>- What SAAG value strongly suggests portal hypertension?</li><li>- What is the diagnostic neutrophil count for SBP?</li><li>- What is the recommended albumin dose per liter removed for paracentesis >5L?</li><li>- How is hyponatremia defined in cirrhosis?</li><li>- For inpatient management of symptomatic hypervolemic hyponatremia, how should fluid intake be restricted?</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Overview & Pathophysiology</strong></summary>
            <div>
                <ul><li>- <u>Volume overload</u> is a defining feature of <u>decompensated cirrhosis</u>.</li><li>- Manifestations: <b>ascites</b>, <b>hepatic hydrothorax (HH)</b>, peripheral edema, anasarca.</li><li>- Complications: Decreased quality of life, hospitalizations, infections, hepatorenal syndrome, increased mortality.</li><li>- <u>Hyponatremia</u> worsens hepatic encephalopathy (HE) and ascites, associated with mortality.</li></ul>
                
        <details>
            <summary><strong>Mechanism of Volume Overload</strong></summary>
            <div>
                <ul><li>- <u>Portal hypertension</u> ---> increased intrahepatic vascular resistance & portal blood flow ---> mesenteric & systemic vasodilation.</li><li>- Kidney responds with <u>neurohormonal activation</u> (Renin-Angiotensin-Aldosterone System) ---> renal sodium & water reabsorption ---> intravascular & interstitial volume expansion.</li><li>- <u>Ascites</u>: Excess fluid leaks into peritoneal cavity due to exceeding hepatic lymphatic capacity, reduced oncotic pressure (hypoalbuminemia), increased hydrostatic pressure (portal hypertension), increased capillary permeability.</li><li>- <u>Hepatic Hydrothorax (HH)</u>: Diaphragmatic defects allow ascitic fluid to enter the pleural space.</li><li>- <u>Hypervolemic Hyponatremia</u>: Progressive circulatory dysfunction & effective intravascular hypovolemia ---> increased renal water retention.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Best Practice Advice 1: General Management of Ascites, HH, Volume Overload</strong></summary>
            <div>
                <ul><li>- Manage with <u>dietary sodium restriction</u> and <u>diuretics</u> at the lowest effective dose.</li><li>- Dose escalation guided by: symptoms, weight, urine output, electrolyte/renal monitoring.</li><li>- Provide education and referral to a <u>dietitian</u> for dietary management.</li><li>- Identify and address <u>triggers of liver decompensation</u> (e.g., alcohol, medications, toxins, hemodynamic changes, infection).</li></ul>
                
        <details>
            <summary><strong>Dietary Management</strong></summary>
            <div>
                <ul><li>- Sodium restriction: ideally <q><b><2000 mg/d</b></q>.</li><li>- Dietitian guidance: label reading, cooking techniques, sodium education.</li><li>- Avoid overly restrictive diets to prevent caloric or protein deficiency.</li><li>- Dietary advice: <q><b>≥35 kcal/kg/d</b></q> (non-obese), micronutrient repletion, protein intake <q><b>1.2–1.5 g/kg</b></q>.</li><li>- <u>Fluid restriction</u> is <b>not needed</b> in the absence of significant hyponatremia.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Diuretic Therapy</strong></summary>
            <div>
                <ul><li>- First-line medications: <u>Mineralocorticoid receptor antagonists</u> (MRA) and <u>loop diuretics</u>.</li><li>- Combined <u>furosemide and spironolactone</u> (40:100 ratio) enhances natriuresis and diuresis while maintaining normokalemia.</li><li>- <u>Spironolactone</u>: Typically started at <q><b>100 mg daily</b></q> (range <q><b>50–400 mg</b></q>), ideally as a once-daily morning dose.</li><li>- Alternatives for spironolactone intolerance: amiloride, eplerenone (less effective).</li><li>- <u>Furosemide</u>: Usually starts at <q><b>40 mg daily</b></q> (range <q><b>20–160 mg</b></q>).</li><li>- Titration: To the lowest effective dose based on weight, symptoms, urine output, and laboratory results.</li><li>- Targeted weight loss: <q><b>0.5 kg/d</b></q> without edema, <q><b>1 kg/d</b></q> with edema.</li><li>- Mild, asymptomatic ascites: May be managed with low-dose diuretics or sodium restriction alone.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Best Practice Advice 2: Diagnostic Paracentesis</strong></summary>
            <div>
                <ul><li>- Indication: <u>New-onset ascites</u>, or hospital admission for symptoms related to ascites or encephalopathy.</li><li>- Timing: As soon as possible.</li><li>- Testing: <u>Serum ascites albumin gradient (SAAG)</u>, <u>cell count</u>, <u>Gram stain</u>, and <u>culture</u>.</li><li>- Paracentesis within <q><b>12–24 hours</b></q> of admission is associated with lower hospital mortality.</li></ul>
                
        <details>
            <summary><strong>SAAG Interpretation</strong></summary>
            <div>
                <ul><li>- SAAG <q><b>≥1.1 g/dL</b></q> strongly suggests <u>portal hypertension</u>.</li><li>- SAAG <q><b><1.1 g/dL</b></q> warrants evaluation for other causes.</li><li>- Patients with heart failure typically have SAAG <q><b>≥1.1 g/dL</b></q> and high ascitic fluid protein (<q><b>>2.5 g/dL</b></q>).</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Spontaneous Bacterial Peritonitis (SBP) Diagnosis</strong></summary>
            <div>
                <ul><li>- SBP is diagnosed when the <u>neutrophil count exceeds <q><b>250/mm3</b></q></u>, with or without culture positivity, and without evidence of secondary peritonitis.</li><li>- Cultures should be obtained by <u>bedside inoculation into blood culture bottles</u>.</li><li>- For low SAAG or non–portal hypertension causes, consider further testing (cytology, amylase, mycobacterial studies).</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Best Practice Advice 3: Therapeutic Thoracentesis for Hepatic Hydrothorax (HH)</strong></summary>
            <div>
                <ul><li>- Indication: Patients with HH with <u>dyspnea</u> and/or <u>hypoxemia</u>.</li><li>- Purpose: Both <u>symptom relief</u> and <u>expansion of the underlying lung</u>.</li><li>- HH is a poor prognostic sign, associated with a <q><b>>4-fold increase in mortality</b></q> compared with refractory ascites.</li><li>- First-line therapies: <u>Sodium restriction</u> and <u>diuretics</u>.</li><li>- Thoracentesis is indicated for symptomatic patients or those with recurrent effusions despite treatment.</li></ul>
                
        <details>
            <summary><strong>Spontaneous Bacterial Empyema (SBE) Diagnosis</strong></summary>
            <div>
                <ul><li>- Hospitalized patients with HH-related symptoms, HE, or unexplained liver decompensation should undergo thoracentesis to evaluate for SBE.</li><li>- SBE is diagnosed when <u>pleural fluid neutrophils exceed <q><b>250/mm3</b></q></u>, with or without culture positivity, and without an alternative infectious source.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Best Practice Advice 4: Liver Transplantation Evaluation</strong></summary>
            <div>
                <ul><li>- All patients with <u>ascites and/or HH</u> should be considered for liver transplantation evaluation, regardless of their Model for End-Stage Liver Disease (MELD) score.</li><li>- Ascites is the most common form of cirrhosis decompensation and a prerequisite for SBP and hepatorenal syndrome, which carry <q><b>90-day mortality rates up to 50%</b></q>.</li><li>- Once ascites develops, annual mortality rises from <q><b><5% to 20%</b></q>.</li><li>- HH is independently associated with significantly higher mortality regardless of MELD, with a <q><b>1-year mortality rate of 20%–50%</b></q>.</li></ul>
                
        <details>
            <summary><strong>MELD Score & HH Exceptions</strong></summary>
            <div>
                <ul><li>- MELD has been revised to include sodium, sex, and albumin.</li><li>- Ascites remains an <u>independent predictor of mortality</u> beyond MELD.</li><li>- Patients with ascites and low MELD scores may access transplants via living donors or extended criteria donors.</li><li>- Organ Procurement and Transplantation Network (OPTN) guidance offers <b>no standard MELD exception for HH</b>.</li><li>- Nonstandard exceptions for HH may be granted individually for patients meeting criteria:</li><li>- <q><b>≥1 thoracentesis >1 L weekly for 4 weeks</b></q>.</li><li>- Transudative fluid.</li><li>- No heart failure.</li><li>- Negative cultures and cytology.</li><li>- Contraindications to TIPS.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Best Practice Advice 5: Management of Refractory Ascites and/or Hydrothorax</strong></summary>
            <div>
                <ul><li>- Manage with <u>therapeutic paracentesis</u> and/or <u>thoracentesis</u>, respectively, with the frequency guided by recurrence.</li><li>- <u>Refractory ascites</u>: Ascites that cannot be mobilized or the early recurrence of which cannot be satisfactorily prevented by medical therapy (See Table 1).</li><li>- <u>Refractory HH</u>: Unresponsive to sodium restriction and diuretic therapy and requires therapeutic thoracentesis (See Table 1).</li></ul>
                
        <details>
            <summary><strong>Refractory Ascites Subcategories</strong></summary>
            <div>
                <ul><li>- <u>Diuretic-resistant</u>: Nonresponse to sodium restriction and diuretics.</li><li>- <u>Diuretic-intractable</u>: Complications that prevent effective diuretic dose escalation.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Therapeutic Paracentesis Considerations</strong></summary>
            <div>
                <ul><li>- Safe, effective, offers faster symptom relief and fewer complications (e.g., HE, electrolyte abnormalities, AKI) compared to intensive diuretic therapy.</li><li>- Large-volume removal can cause <u>postparacentesis circulatory dysfunction (PCD)</u>, increasing risks of kidney injury, electrolyte imbalances, HE, and death.</li><li>- Postparacentesis bleeding is rare; <u>prophylactic transfusions are <b>not advised</b></u>.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Therapeutic Thoracentesis Considerations for HH</strong></summary>
            <div>
                <ul><li>- More challenging than ascites due to lower fluid thresholds for symptoms.</li><li>- Carries higher risks (e.g., bleeding, infection, pneumothorax, re-expansion edema) than for other effusion causes.</li><li>- Bleeding from chest wall portosystemic collaterals can be catastrophic.</li><li>- Risks of complications and death rise with repeated thoracenteses.</li><li>- <u>Chest tube placement for HH carries high morbidity and mortality and should be <b>avoided</b></u>.</li><li>- <u>Indwelling tunneled pleural catheters</u>: Show promise, relatively low complication rates; may serve as palliative options or a bridge to transplantation.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Best Practice Advice 6: Albumin Administration Post-Paracentesis</strong></summary>
            <div>
                <ul><li>- When the volume of ascites removed is <q><b>>5 L</b></q>, <q><b>20%–25% intravenous albumin 6–8 g per every total liter removed</b></q> should be administered.</li><li>- Purpose: Prevent <u>postparacentesis circulatory dysfunction (PCD)</u>, which reduces electrolyte derangements and mortality.</li><li>- For patients with <u>hypotension</u>, <u>renal insufficiency</u>, or <u>electrolyte abnormalities</u>, albumin should also be considered for removal of smaller volumes.</li><li>- A more liberal albumin strategy (lower-volume thresholds, higher doses) may be considered case by case in this population, with care to avoid iatrogenic volume overload.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Best Practice Advice 7: Transjugular Intrahepatic Portosystemic Shunt (TIPS)</strong></summary>
            <div>
                <ul><li>- Indication: Well-selected patients with <u>refractory ascites</u>, <u>hepatic hydrothorax</u>, <u>volume overload</u>, or <u>hyponatremia</u>.</li><li>- Effectiveness: Highly effective for portal hypertension, more effective than paracentesis in controlling ascites, and associated with lowermortality.</li><li>- Impact on patient-reported outcomes is less clear; symptom relief may be offset by HE and TIPS dysfunction risk.</li></ul>
                
        <details>
            <summary><strong>Patient Selection & Contraindications</strong></summary>
            <div>
                <ul><li>- <u>Absolute contraindications</u>: <b>Congestive heart failure</b>, <b>severe pulmonary hypertension</b>, <b>uncontrolled HE</b>, and <b>sepsis</b>.</li><li>- Avoid in patients with: <u>Ejection fraction <q><b><50%</b></q></u>, severe diastolic/valvular dysfunction, or <u>right ventricular systolic pressure <q><b>>45 mm Hg</b></q></u>.</li><li>- <u>HE occurs in up to <q><b>50%</b></q> post-TIPS</u>. Risk factors: prior HE, impaired liver function, older age, renal dysfunction, hyponatremia, large gradient reduction, sarcopenia.</li><li>- Caution advised for patients <q><b>older than 70 years</b></q> or with <u>MELD score <q><b>>18</b></q></u>.</li><li>- <u>Cardiac decompensation</u> may occur in up to <q><b>20%</b></q> within 1 year of TIPS.</li><li>- Preprocedural evaluation: Echocardiography for cardiac systolic/diastolic function and right ventricular systolic pressure.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>TIPS Timing & Alternatives</strong></summary>
            <div>
                <ul><li>- Optimal TIPS timing remains undefined; most studies focus on refractory ascites and HH.</li><li>- Some expert panels suggest TIPS after <q><b>3 large-volume paracenteses in 12 months</b></q>, especially with other indications (e.g., prior variceal bleeding).</li><li>- For refractory ascites patients <u>not eligible for TIPS</u>:</li><li>- <u>Indwelling peritoneal catheters</u>: Limited evidence, potentially high complication rates.</li><li>- <u>Alfapump</u>: Improved quality of life in trials, but carries infection risk.</li><li>- <u>Peritoneovenous shunt</u>: Limited by concerns regarding shunt patency, DIC, heart failure.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Best Practice Advice 8: Diagnostic Workup for Hyponatremia</strong></summary>
            <div>
                <ul><li>- Etiology of hyponatremia in cirrhosis: <u>Serum overdilution</u> from fluid retention caused by vasopressin secretion, increased water reabsorption, and enhanced sodium reabsorption.</li><li>- Workup should include:</li><li>- <u>Dietary and medication history</u> (diuretics, bowel regimen).</li><li>- Review of <u>electrolyte and kidney function</u>.</li><li>- <u>Gastrointestinal bleeding assessment</u>.</li><li>- <u>Infectious workup</u>, including diagnostic paracentesis.</li><li>- Evaluation of <u>secondary causes</u> (thyroid or adrenal dysfunction).</li><li>- Hyponatremia (serum sodium <q><b><130 mEq/L</b></q>) is associated with significant morbidity and mortality.</li><li>- <u>Pseudohyponatremia</u>: Consider if serum osmolality is <b>not low</b> (<q><b>>280 mOsm/L</b></q>).</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Best Practice Advice 9: Outpatient Management of Asymptomatic Hypervolemic Hyponatremia</strong></summary>
            <div>
                <ul><li>- Indication: Asymptomatic hypervolemic hyponatremia in liver cirrhosis.</li><li>- Management entails:</li><li>- Both <u>sodium and water restriction</u> (aiming for <q><b>1–1.5 L of daily fluid intake</b></q>).</li><li>- <u>Modification of diuretics and laxatives</u>.</li><li>- <u>Monitoring of electrolytes</u>.</li><li>- If asymptomatic with mild hyponatremia (serum sodium <q><b>>120 mEq/L</b></q>), fluid intake can be limited to <q><b>1–1.5 L</b></q>.</li><li>- Diuretics often need to be reduced or discontinued; can resume/maintain once sodium stabilizes <q><b>>125 mEq/L</b></q>.</li><li>- Patient education on lactulose/laxative dosing is important to avoid excessive stooling, which can lead to volume depletion and worsening hyponatremia.</li><li>- Ambulatory albumin infusions may help, but access is limited.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Best Practice Advice 10: Inpatient Management of Severe or Symptomatic Hypervolemic Hyponatremia</strong></summary>
            <div>
                <ul><li>- Indication: Patients with symptoms related to hyponatremia or serum sodium falls <q><b>below 120 mEq/L</b></q>.</li><li>- Management includes:</li><li>- Both <u>sodium and water restriction</u>.</li><li>- <u>Modification or discontinuation of diuretics and laxatives</u>.</li><li>- Additional measures: <u>intravenous albumin</u> (based on volume assessment) or <u>oral vasoconstriction therapy</u> (e.g., midodrine).</li><li>- Symptoms can include cognitive changes, dizziness, seizures, cardiopulmonary alterations, nausea, and vomiting.</li><li>- <u>Hypokalemia should be corrected</u>, especially with encephalopathy.</li><li>- Fluid intake should be restricted to be <u>less than urine output</u>.</li><li>- In hypotension (systolic BP <q><b><90 mm Hg</b></q>), nonselective beta-blockers may need to be held.</li><li>- For life-threatening hyponatremia or pre-transplant correction: Cautious <q><b>3% hypertonic saline</b></q> use, avoiding rapid correction to prevent osmotic demyelination syndrome.</li><li>- <u>Selective vasopressin antagonists (vaptans)</u>: Use has declined due to adverse events (hepatic injury, mortality); reserved mainly for <u>short-term use in severe hyponatremia awaiting liver transplantation</u>.</li><li>- In severe kidney injury, <u>hemodialysis</u> may help correct hyponatremia.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Best Practice Advice 11: Recurrent or Refractory Hyponatremia Management</strong></summary>
            <div>
                <ul><li>- Indication: Recurrent or refractory hyponatremia in cirrhosis.</li><li>- Management should involve a <u>multidisciplinary approach</u> (including liver transplantation team).</li><li>- Therapeutic options: <u>Intravenous vasoconstrictor therapy</u> (e.g., terlipressin or norepinephrine), <u>infusion of hypertonic saline</u>, use of <u>vasopressin receptor antagonist (vaptans)</u>, or use of <u>renal replacement therapy</u>.</li><li>- Recurrent hyponatremia: Redevelopment after a prior episode.</li><li>- Refractory hyponatremia: Persistence despite maximal therapy.</li><li>- Hyponatremia recurs in <q><b>>50% of cases</b></q> and is associated with poor survival.</li><li>- If transplantation is not an option, palliative care and hepatology teams can help address goals of care and symptom management.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Best Practice Advice 12: Inpatient Management of Volume Overload</strong></summary>
            <div>
                <ul><li>- Indication: Anasarca with or without ascites or HH, especially when progressing despite outpatient diuretics or with persistent signs of anasarca.</li><li>- Management includes:</li><li>- Reversal of aggravating factors (e.g., alcohol, NSAIDs).</li><li>- Dietary sodium restriction.</li><li>- Medication review (including anti-hypertensives, especially RAS inhibitors).</li><li>- <u>Diuresis</u>: Escalation or trial of <u>intravenous loop diuretics</u> (furosemide or bumetanide) in bolus (<q><b>2–3 times per day</b></q>) or continuous fashion.</li><li>- Cautious escalation: Every <q><b>2–3 days</b></q> with monitoring of volume status, kidney function, daily weights, and symptoms.</li><li>- IV furosemide is approximately <q><b>twice as potent as oral</b></q>; bumetanide may have <q><b>1:1 oral-to-intravenous equivalence</b></q>.</li><li>- The role of concurrent intravenous albumin is unclear; targeting a serum albumin level does not reduce infection, kidney dysfunction, or death in patients not admitted specifically for volume overload.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Best Practice Advice 13: Advanced Strategies in Refractory Anasarca</strong></summary>
            <div>
                <ul><li>- Indication: Inadequate response to initial diuretic therapy.</li><li>- Strategies should be coordinated with <u>nephrology</u>.</li><li>- Considerations:</li><li>- Diuretics in the setting of <u>contraction alkalosis</u> (e.g., addition of <u>acetazolamide</u>).</li><li>- Second agent with alternate mechanism of action (e.g., <u>thiazide diuretics, such as metolazone</u>).</li><li>- Need for <u>ultrafiltration</u>.</li><li>- Adverse events that may limit diuresis: Contraction alkalosis and electrolyte dysfunction.</li><li>- Elevation in serum creatinine is common but may not necessarily reflect worsening kidney function.</li><li>- In diuretic-resistant anasarca (no improvement despite maximal diuretics and persistently low urine sodium), advanced strategies include <u>pressors to augment diuresis</u> in the ICU.</li><li>- <u>Ultrafiltration</u> may be considered in select cases, especially for liver transplantation candidates.</li><li>- <u>Transitional care</u> on discharge (medication management, patient/caregiver education, timely follow-up) is important.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Conclusions and Future Directions</strong></summary>
            <div>
                <ul><li>- <u>Liver transplantation</u> remains the only curative option.</li><li>- Strategies are needed to bridge patients to transplantation or improve quality of life for those without timely access.</li><li>- Investigational therapeutic trials are especially needed for patients with <u>advanced steatotic liver disease</u>.</li><li>- Further refinement of disease definitions is needed for earlier recognition and appropriate management.</li><li>- Gastroenterologists and hospitalists must know when and how to provide optimal care and timely hepatology referral to prevent higher mortality, readmissions, and poor outcomes.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
    </div>
    
</div>

<br>
<br>
<br>
<br>
<br>


<script>
// --- State Management for Expansion Level ---
let currentLevel = 1; 
const maxLevel = 10;
const minLevel = 1;

// --- Core Function to Set Mindmap Expansion ---
function setMindmapLevel(level) {
    const allDetails = document.querySelectorAll('.mindmap details');
    allDetails.forEach(detail => detail.removeAttribute('open'));
    allDetails.forEach(detail => {
        let depth = 0;
        let parent = detail.parentElement;
        while (parent && parent.tagName !== 'BODY') {
            if (parent.tagName === 'DETAILS') {
                depth++;
            }
            parent = parent.parentElement;
        }
        if (depth < level) {
            detail.setAttribute('open', '');
        }
    });
}

// --- Control Functions ---
function zoomIn() {
    if (currentLevel < maxLevel) {
        currentLevel++;
        setMindmapLevel(currentLevel);
    }
}

function zoomOut() {
    if (currentLevel > minLevel) {
        currentLevel--;
        setMindmapLevel(currentLevel);
    }
}

function resetView() {
    currentLevel = minLevel;
    setMindmapLevel(currentLevel);
}


// --- NEW: Function to Toggle Read/Quiz Mode ---
function toggleReadMode() {
    const mindmapContainer = document.querySelector('.mindmap');
    if (mindmapContainer) {
        mindmapContainer.classList.toggle('read-mode');
    }
}

// --- Draggable Controls ---
function dragElement(elmnt) {
    let pos1 = 0, pos2 = 0, pos3 = 0, pos4 = 0;
    const onMouseDown = (e) => {
        e = e || window.event;
        e.preventDefault();
        pos3 = e.clientX;
        pos4 = e.clientY;
        document.onmouseup = closeDragElement;
        document.onmousemove = elementDrag;
    };
    const elementDrag = (e) => {
        e = e || window.event;
        e.preventDefault();
        pos1 = pos3 - e.clientX;
        pos2 = pos4 - e.clientY;
        pos3 = e.clientX;
        pos4 = e.clientY;
        elmnt.style.top = (elmnt.offsetTop - pos2) + "px";
        elmnt.style.left = (elmnt.offsetLeft - pos1) + "px";
        elmnt.style.transform = "none";
        elmnt.style.bottom = "auto";
    };
    const closeDragElement = () => {
        document.onmouseup = null;
        document.onmousemove = null;
    };
    if (document.getElementById(elmnt.id)) {
        document.getElementById(elmnt.id).onmousedown = onMouseDown;
    } else {
        elmnt.onmousedown = onMouseDown;
    }
}




// --- Initial Setup ---
window.addEventListener('DOMContentLoaded', () => {
    // Set the initial mindmap view
    setMindmapLevel(currentLevel);

    // Get the draggable controls element
    const controls = document.getElementById('level-controls');
    if (controls) {
        dragElement(controls);
    }

    // --- CORRECTED & IMPROVED: Setup for Click-to-Reveal ---
    const mindmapContainer = document.querySelector('.mindmap');
    if (mindmapContainer) {
        mindmapContainer.addEventListener('click', function(event) {
            // Use .closest() to find the nearest parent <q> tag.
            // This is more robust than checking event.target.tagName.
            const quoteElement = event.target.closest('q');
            
            if (quoteElement) {
                // Add the 'is-revealed' class to show the text
                quoteElement.classList.add('is-revealed');
            }
        });
    }
});
</script>

</body>
</html>
